You will be given SPALBORT 3,5 mg intravenously or subcutaneously (under the skin).
SPALBORT 3,5 mg is for intravenous or subcutaneous use.
You will receive SPALBORT 3,5 mg in a specialised medical unit, under the supervision of a doctor experienced in the use of cytotoxic medicinal products.
SPALBORT 3,5 mg powder has to be dissolved before administration. This will be done by a healthcare professional. The resulting solution is then either injected into a vein or under the skin.
Injection into the vein is rapid, taking 3 to 5 seconds.
Injection under the skin is in either the thigh or the abdomen.
The dose will be calculated from your height and weight (body surface area).
Monotherapy
When SPALBORT 3,5 mg is given alone, one cycle of treatment with SPALBORT 3,5 mg consists of a total of 4 doses. Doses are given on days 1, 4, 8 and 11, followed by a 10-day ‘rest period’ without treatment.
Therefore, the duration of a treatment cycle is 21 days (3 weeks).
Combination therapy
If you have not been treated before for multiple myeloma, you will receive SPALBORT 3,5 mg together with two other medicines containing melphalan and prednisone.
In this case, the duration of a cycle is 6 weeks. The treatment consists of a total of 9 cycles (54 weeks).
- In cycles 1 to 4, SPALBORT 3,5 mg is administered twice weekly on days 1, 4, 8, 11, 22, 25, 29 and 32.
- In cycles 5 to 9, SPALBORT 3,5 mg is administered once weekly on days 1, 8, 22 and 29.
Melphalan and prednisone are both given orally on days 1, 2, 3 and 4 of the first week of each cycle.
If you receive more SPALBORT 3,5 mg than you should:
Since a healthcare professional will administer SPALBORT 3,5 mg, he/she will control the dosage. In the event of overdosage, the doctor will treat you.
If you miss a dose of SPALBORT 3,5 mg:
SPALBORT 3,5 mg will be administered under your doctor’s supervision. If you think you have not been given a dose of SPALBORT 3,5 mg, tell your doctor or other healthcare professional immediately.